These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22415888)

  • 1. Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression.
    Vardeny O; Pouleur AC; Takeuchi M; Appelbaum E; Verma A; Prescott M; Smith B; Dahlof B; Solomon SD;
    J Renin Angiotensin Aldosterone Syst; 2012 Jun; 13(2):265-72. PubMed ID: 22415888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension.
    Pouleur AC; Uno H; Prescott MF; Desai A; Appelbaum E; Lukashevich V; Smith BA; Dahlöf B; Solomon SD;
    J Renin Angiotensin Aldosterone Syst; 2011 Dec; 12(4):483-90. PubMed ID: 21746765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.
    Solomon SD; Appelbaum E; Manning WJ; Verma A; Berglund T; Lukashevich V; Cherif Papst C; Smith BA; Dahlöf B;
    Circulation; 2009 Feb; 119(4):530-7. PubMed ID: 19153265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
    Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
    Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.
    Persson F; Lewis JB; Lewis EJ; Rossing P; Hollenberg NK; Hans-Henrik P
    J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):118-21. PubMed ID: 21824990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
    Uresin Y; Taylor AA; Kilo C; Tschöpe D; Santonastaso M; Ibram G; Fang H; Satlin A
    J Renin Angiotensin Aldosterone Syst; 2007 Dec; 8(4):190-8. PubMed ID: 18205098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
    Dietz R; Dechend R; Yu CM; Bheda M; Ford J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):163-75. PubMed ID: 18957387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Dahlof B;
    Circulation; 2003 Aug; 108(6):684-90. PubMed ID: 12885747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular systolic and diastolic function, remodelling, and clinical outcomes among patients with diabetes following myocardial infarction and the influence of direct renin inhibition with aliskiren.
    Shah AM; Shin SH; Takeuchi M; Skali H; Desai AS; Køber L; Maggioni AP; Rouleau JL; Kelly RY; Hester A; Keefe D; McMurray JJ; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2012 Feb; 14(2):185-92. PubMed ID: 21965526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different effects of aliskiren and losartan on fibrinolysis and insulin sensitivity in hypertensive patients with metabolic syndrome.
    Fogari R; Zoppi A; Mugellini A; Lazzari P; Derosa G
    Horm Metab Res; 2010 Nov; 42(12):892-6. PubMed ID: 20814848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
    Andersen K; Weinberger MH; Constance CM; Ali MA; Jin J; Prescott MF; Keefe DL
    J Renin Angiotensin Aldosterone Syst; 2009 Sep; 10(3):157-67. PubMed ID: 19617271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
    Mazza A; Montemurro D; Zuin M; Schiavon L; Zorzan S; Chondrogiannis S; Ferretti A; Ramazzina E; Rubello D
    Minerva Cardioangiol; 2013 Aug; 61(4):461-9. PubMed ID: 23846012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.
    Solomon SD; Shin SH; Shah A; Skali H; Desai A; Kober L; Maggioni AP; Rouleau JL; Kelly RY; Hester A; McMurray JJ; Pfeffer MA;
    Eur Heart J; 2011 May; 32(10):1227-34. PubMed ID: 21317148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aliskiren on blood pressure and the predictive biomarkers for cardiovascular disease in hemodialysis-dependent chronic kidney disease patients with hypertension.
    Morishita Y; Hanawa S; Chinda J; Iimura O; Tsunematsu S; Kusano E
    Hypertens Res; 2011 Mar; 34(3):308-13. PubMed ID: 21124333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrasting effects of aliskiren versus losartan on hypertensive vascular remodeling.
    Martins-Oliveira A; Castro MM; Oliveira DM; Rizzi E; Ceron CS; Guimaraes D; Reis RI; Costa-Neto CM; Casarini DE; Ribeiro AA; Gerlach RF; Tanus-Santos JE
    Int J Cardiol; 2013 Aug; 167(4):1199-205. PubMed ID: 22483258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Nieminen MS; Olsen MH; Okin PM; Palmieri V; Rokkedal JE; Devereux RB
    Blood Press; 2010 Jun; 19(3):169-75. PubMed ID: 20438307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Managing cardiovascular and renal risk: the potential of direct renin inhibition.
    Sever PS; Gradman AH; Azizi M
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):65-76. PubMed ID: 19502253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.